Last updated
Cerebrolysin and Semax are both neuroprotective agents used clinically outside the United States — often for the same indication, stroke recovery — but they could hardly be more different as molecules. One is a defined mixture of many brain-derived fragments; the other is a single seven-residue peptide. And they approach neurotrophic support from opposite directions.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | Cerebrolysin | Semax |
|---|---|---|
| What it is | Standardized porcine-brain peptide/amino-acid mixture | Single synthetic heptapeptide (ACTH(4-10) analog) |
| Composition | ~15% low-MW peptides + ~85% free amino acids | One defined sequence (MEHFPGP) |
| Neurotrophic approach | Mimics endogenous factors (BDNF, NGF, GDNF) | Induces the body to make BDNF / NGF |
| Route | Injectable (IV / IM) | Intranasal |
| Lead indications | Stroke, traumatic brain injury, dementia | Stroke, cognitive impairment, optic-nerve disease |
| Regulatory status | Approved in ~44 countries (not FDA) | Approved in Russia (not FDA) |
| Molecular identity | No single formula — a defined mixture | 7-aa peptide |
| FDA approval | None (US) | None (US) |
Cerebrolysin is one of the few entries here that is not a single peptide at all but a defined biological mixture — low-molecular-weight neuropeptides (about 15%) and free amino acids (about 85%), produced by controlled enzymatic breakdown of purified pig-brain proteins and standardized by peptide-nitrogen content. Its small peptide fraction can cross the blood–brain barrier, where it is proposed to reproduce, in part, the actions of the brain’s own neurotrophic factors — BDNF, NGF, GDNF. It has one of the largest clinical literatures of any nootropic, is delivered by injection, and is approved in roughly 44 countries for stroke, traumatic brain injury, and dementia.
Semax reaches a related goal from the other end. Rather than supplying neurotrophic-like material, this single ACTH(4-10) heptapeptide induces the body to raise its own BDNF and NGF, alongside monoaminergic effects, without activating the stress axis — and it is given intranasally. It is approved in Russia for stroke, cognitive impairment, and optic-nerve disease. So the mechanistic split is neat: Cerebrolysin is broad neurotrophic replacement in a syringe; Semax is targeted neurotrophic induction in a nasal spray. Both share the same caveat — used and approved abroad, but not FDA-approved, with Western controlled evidence that remains debated.
Two neuroprotective agents that meet at the same indications by different routes and different chemistry. Cerebrolysin is an injectable, broad porcine-brain neurotrophic mixture with a large but debated clinical literature and approval in dozens of countries; Semax is a single intranasal neuropeptide that induces the body’s own neurotrophic factors, approved in Russia. Neither is FDA-approved, and for both the honest limitation is the strength and independence of the controlled evidence. This page is a research and educational reference.
Cerebrolysin is a standardized mixture of small peptides and amino acids made from porcine brain, given by injection, that mimics neurotrophic factors like BDNF and NGF. Semax is a single synthetic ACTH(4-10) peptide, given intranasally, that induces the body to produce those factors. One supplies neurotrophic-like material; the other triggers it.
They overlap — both are used abroad for stroke recovery and cognition. Cerebrolysin is also used for traumatic brain injury and dementia; Semax is also approved in Russia for optic-nerve disease. Neither is FDA-approved in the US.
Not a single one — it is a defined biological mixture (about 15% low-molecular-weight peptides and 85% free amino acids), so it has no single sequence or molecular formula. Semax, by contrast, is one seven-residue peptide.
No. Cerebrolysin is approved in roughly 44 countries and Semax in Russia, but neither is FDA-approved in the United States. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between Cerebrolysin and Semax — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.